Study shows biomarkers can predict which ER-positive breast cancer patients respond best to first-line therapy

(University of Texas M. D. Anderson Cancer Center) Two challenges in treating patients with estrogen-positive breast cancer (ER+) have been an inability to predict who will respond to standard therapies and adverse events leading to therapy discontinuation. A study at The University of Texas MD Anderson Cancer Center revealed new information about how the biomarkers retinoblastoma protein (Rb) and cytoplasmic cyclin E could indicate which patients will respond best to current first-line therapies.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news